Articles related to PROSTATE CANCER

The results of PROfound and PROpel underscore the importance of identifying the genomic characteristics of the patient and the cancer to guide the selection of the most appropriate treatment for a specific patient type.

The prevalence of HRR deficiencies has been found to be as high as 20% to 30% in patients with mCRPC, a significantly higher rate than that in patients with localized disease.

Although genomic classifier tests for prostate cancer show promise, a systematic review of 22 studies reveals marked differences between observational and trial data in how these tests influence risk stratification and treatment selection.

This refined surgical technique for robotic-assisted laparoscopic radical prostatectomy focuses on preserving vital supportive structures while effectively removing the prostate, potentially enhancing post-operative outcomes.

Recent research suggests that transperineal prostate biopsies can be safely performed without antibiotics, potentially offering an alternative to traditional transrectal biopsies for cancer detection and monitoring.

MacroGenics’ Phase II TAMARACK trial for vobramitamab duocarmazine in metastatic prostate cancer reported five patient deaths, raising critical safety concerns but also highlighting promising response rates that could influence future treatment protocols.